Cargando…

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma

Loss of the chromosomal region 8p21 negatively effects survival in patients with multiple myeloma (MM) that undergo autologous stem cell transplantation (ASCT). In this study, we aimed to identify the immunological and molecular consequences of del(8)(p21) with regards to treatment response and bort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duru, Adil Doganay, Sutlu, Tolga, Wallblom, Ann, Uttervall, Katarina, Lund, Johan, Stellan, Birgitta, Gahrton, Gösta, Nahi, Hareth, Alici, Evren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574561/ https://www.ncbi.nlm.nih.gov/pubmed/26378933 http://dx.doi.org/10.1371/journal.pone.0138248

Ejemplares similares

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
por: Uttervall, Katarina, et al.
Publicado: (2014)

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
por: Chrobok, Michael, et al.
Publicado: (2019)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Correction: Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells
por: Rossi, Fiorella, et al.
Publicado: (2021)

Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
por: Susek, Katharina Helene, et al.
Publicado: (2020)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
por: Gran, Charlotte, et al.
Publicado: (2020)

Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
por: Sayitoglu, Ece Canan, et al.
Publicado: (2020)

Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
por: Gran, Charlotte, et al.
Publicado: (2020)

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
por: Gahrton, Gösta
Publicado: (2023)

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
por: Jakobsen Falk, Ingrid, et al.
Publicado: (2017)

Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells
por: Sanlioglu, Ahter D, et al.
Publicado: (2005)

The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells
por: Ryu, Sunhyo, et al.
Publicado: (2018)

Reduction of Decoy Receptor 3 Enhances TRAIL-Mediated Apoptosis in Pancreatic Cancer
por: Wang, Wei, et al.
Publicado: (2013)

Synergistic apoptosis of human gastric cancer cells by bortezomib and TRAIL
por: Bui, Hang Thi Thuy, et al.
Publicado: (2019)

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
por: Susek, Katharina H., et al.
Publicado: (2022)

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
por: Bhutani, Manisha, et al.
Publicado: (2023)

TRAIL Death Receptor-4, Decoy Receptor-1 and Decoy Receptor-2 Expression on CD8(+ )T Cells Correlate with the Disease Severity in Patients with Rheumatoid Arthritis
por: Bisgin, Atil, et al.
Publicado: (2010)

Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link
por: Fulda, Simone
Publicado: (2011)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity
por: Dahlberg, Carin I. M., et al.
Publicado: (2015)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells
por: Rossi, Fiorella, et al.
Publicado: (2020)

Buried treasure—marine turtles do not ‘disguise’ or ‘camouflage’ their nests but avoid them and create a decoy trail
por: Burns, Thomas J., et al.
Publicado: (2020)

Correction to ‘Buried treasure—marine turtles do not “disguise” or “camouflage” their nests but avoid them and create a decoy trail’
por: Burns, Thomas J., et al.
Publicado: (2020)

TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer
por: Karahan, Zeynep Sena, et al.
Publicado: (2023)

Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism
por: Bullenkamp, J, et al.
Publicado: (2014)

DecoyFinder, a tool for finding decoy molecules
por: Adrià, Cereto Massagué, et al.
Publicado: (2012)

Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
por: Gahrton, Gösta, et al.
Publicado: (2020)

Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes
por: Hebb, Andrea L. O., et al.
Publicado: (2010)

HIV Infection Enhances TRAIL-Induced Cell Death in Macrophage by Down-Regulating Decoy Receptor Expression and Generation of Reactive Oxygen Species
por: Zhu, Dan-Ming, et al.
Publicado: (2011)

Decoy TRAIL receptor CD264: a cell surface marker of cellular aging for human bone marrow-derived mesenchymal stem cells
por: Madsen, Sean D., et al.
Publicado: (2017)

Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking
por: Mysinger, Michael M., et al.
Publicado: (2012)

Inorganic Kernel-Reconstituted Lipoprotein Biomimetic Nanovehicles Enable Efficient Targeting “Trojan Horse” Delivery of STAT3-Decoy Oligonucleotide for Overcoming TRAIL Resistance
por: Shi, Kai, et al.
Publicado: (2017)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Chemokine decoy receptors in inflammation
por: Graham, G
Publicado: (2005)

Cellular decoys distract coronavirus
por: Bradley, David
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1dmriplb8hh8uf4b93jejk2jto